Skip to main content
. 2011 Dec;339(3):757–767. doi: 10.1124/jpet.111.185769

Fig. 7.

Fig. 7.

The effect of cannabinoid and βAR ligands on IOP in CB1(−/−) mice on a CD1 genetic background. A, mean IOP measured from male wild-type CD1 mice after topical application of the appropriate vehicle or timolol (0.5%), WIN (1.0%), or CP (1.0%). ***, p < 0.001 compared with appropriate vehicle control. B, mean IOP measured in male CD1-CB1(−/−) mice after treatment with vehicle and timolol (0.5%; n = 8), WIN (1%; n = 8), or dorzolamide (1.0%; n = 8). ***, p < 0.001; *, p < 0.05 compared with the appropriate vehicle control. C, IOP measured from male CD1-CB1(−/−) mice after topical treatment with vehicle, WIN (1.0%), or CP (1.0%) in the absence or presence of pretreatment with the CB2 antagonist AM630. ***, p < 0.001 compared with the appropriate vehicle control. φ, p < 0.05 compared with non-AM630-treated vehicle.